Navigation Links
Director's Forum: PEPFAR and the Global AIDS Response
Date:9/17/2007

To be webcast live at http://www.wilsoncenter.org/globalhealth

WASHINGTON, Sept. 17 /PRNewswire-USNewswire/ -- Earlier this year, President George W. Bush called for a reauthorization of the President's Emergency Plan for AIDS Relief (PEPFAR), which is set to expire at the end of fiscal year 2008. The plan calls for an increase in funding from the initial 2003 commitment of $15 billion to $30 billion over the next five years.

On September 20, 2007, the Woodrow Wilson Center's Global Health Initiative and Environmental Change and Security Program will co-host a discussion on PEPFAR principles and the global AIDS response, featuring Dr. Peter Piot, Executive Director of UNAIDS and Under Secretary-General of the United Nations, U.S. Representative Nita M. Lowey of New York's 18th District, and Kent R. Hill, Assistant Administrator for the Bureau for Global Health at the U.S. Agency for International Development (USAID).

If you are unable to attend, this event will be webcast live at http://www.wilsoncenter.org/globalhealth.

What: Director's Forum: PEPFAR and the Global AIDS Response

Who: Dr. Peter Piot, Executive Director, UNAIDS, and Under

Secretary-General, United Nations; The Honorable Nita M.

Lowey, U.S. Representative, 18th District, New York, and

Chairwoman of the State, Foreign Operations, and Related

Programs Subcommittee on Appropriations; and Kent R. Hill,

Assistant Administrator for Global Health, USAID

When: Thursday, September 20, 2007, 10:00 - 11:30 a.m.

Where: Woodrow Wilson Center, 6th Floor Flom Auditorium

The Woodrow Wilson Center is located in the Ronald Reagan

Building and International Trade Center at 1300 Pennsylvania

Avenue, N.W.

Space is limited; please RSVP to globalhealth@wilsoncenter.org with your name and affiliation. Media with questions should contact Sharon McCarter at sharon.mccarter@wilsoncenter.org or (202) 691-4016.

The Woodrow Wilson International Center for Scholars is the living, national memorial to President Wilson established by Congress in 1968 and headquartered in Washington, D.C. The Center establishes and maintains a neutral forum for free, open, and informed dialogue. It is a nonpartisan institution, supported by public and private funds and engaged in the study of national and world affairs.


'/>"/>
SOURCE Woodrow Wilson International Center for Scholars
Copyright©2007 PR Newswire.
All rights reserved

Related medicine technology :

1. The International Myeloma Foundation Says Data Reported at a Global Medical Meeting in Greece Demonstrates Improved Survival for a Wide Range of Myeloma Patients
2. New Report Looking at Chiral Technologies Analyzes the Global Market Growth Forecasts Driven By Two Very Important Components as Single Isomer Drugs and Single Enantiomer Pharmaceuticals
3. New Study Reveals Limitations of a Complex and Challenging Global Tuberculosis Drug Marketplace
4. Global Rabies Treatment May be Possible with NanoViricides Drugs
5. Response Genetics Announces Publication of a Phase III Clinical Trial Demonstrating That Low Levels of ERCC-1 Help to Predict Likelihood of Response to Cisplatin-Based Therapy in Lung Cancer
6. TMC125 Showed Significant Virologic Response at Week 24 in Treatment-Experienced HIV Patients With NNRTI Resistance in Phase 3 Trials
7. Trexima (Sumatriptan/Naproxen Sodium) Demonstrated Migraine-Free Response Across Multiple Attacks
8. Cervarix, the GSK Cervical Cancer Candidate Vaccine, Provides Sustained Immune Response in 100 Percent of Women up to 55 Years of Age
9. Data Demonstrated Metastatic Melanoma Response to Investigational Immunotherapy Ipilimumab
10. Ontak (denileukin diftitox) Achieves 49.1% Overall Response Rate in Phase III Trial of Cutaneous T-Cell Lymphoma (CTCL)
11. Introgen Reports Updated Phase 2 Advexin Data Correlating Improved Survival, Tumor Responses and Predictive p53 Biomarker
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/20/2017)... Research and Markets has announced the ... Market Analysis By Service (Manufacturing, Research), By Country, (Brazil, Mexico, ... report to their offering. ... The Latin American pharmaceutical contract manufacturing services market ... Low drug registration cost in Latin American countries and ...
(Date:4/19/2017)... NEW YORK , April 19, 2017 Cardiology ... during the projected period The Cardiology Devices segment ... more than US$ 15 Mn in 2018 over 2017. By ... reach a market valuation close to US$ 700 Mn, expanding ... Cardiology Devices segment dominated the Asia Pacific ...
(Date:4/19/2017)... 19, 2017  IRIDEX Corporation (Nasdaq: IRIX ... for the first quarter 2017 after the close of ... team will host a corresponding conference call beginning at ... Investors interested in listening to the conference call may ... or (703) 326-3030 for international callers, using conference ID: ...
Breaking Medicine Technology:
(Date:4/26/2017)... ... April 26, 2017 , ... Journal of Oral Implantology ... have severe consequences to overall dental health, including complications with speech, eating, and overcompensation ... dental implants to replace lost teeth. As the number of tooth replacements increase, it ...
(Date:4/26/2017)... ... April 26, 2017 , ... ... Hackensack, N.J. has been honored by Enterprising Women magazine as one of its ... world’s top women business owners. Winners have demonstrated that they have fast-growth businesses, ...
(Date:4/26/2017)... (PRWEB) , ... April 26, 2017 , ... RawTrition now ... easy way to get nutrients from SUPERFOODS! , RawTrition is taking nutrients ... the cellular level because the body recognizes its raw form (unlike the synthetically made ...
(Date:4/26/2017)... ... 26, 2017 , ... MYOLYN, a medical technology company dedicated ... received 510(k) clearance from the U.S. Food & Drug Administration (FDA) for two ... devices are stationary cycling systems that use MYOLYN’s patent-pending functional electrical stimulation ...
(Date:4/25/2017)... ... April 25, 2017 , ... ... Newport Beach, California, committed to raising awareness for Duchenne muscular dystrophy, and ... its randomized CAP-1002 (cardiosphere-derived cells) Phase I/II HOPE clinical trial in Duchenne ...
Breaking Medicine News(10 mins):